GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors
10 September 2020 - 9:00PM
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the
science, development, and commercialization of cannabinoid
prescription medicines today announced the appointment of David
Gryska to the Board of Directors. Mr. Gryska will also serve as a
member of the Audit Committee. Mr. Gryska brings valuable global
pharmaceutical and biotechnology industry experience and
executive-level financial leadership to GW’s Board.
“I am very pleased to welcome David to our Board
of Directors,” stated Dr. Geoffrey Guy, GW’s Founder and Chairman
of the Board. “As a highly regarded leader in the biopharmaceutical
industry, we look forward to benefiting from David’s wealth of
experience as we continue to grow commercially and advance our
pipeline with the goal of bringing breakthrough medicines to
patients with significant unmet needs.”
“I am excited to be joining GW’s Board at a time
of commercial growth and product pipeline expansion,” said Mr.
Gryska. “GW has clearly established itself as the global leader in
cannabinoid science, and I am excited at its prospects. I very much
look forward to contributing to its future success.”
Mr. Gryska has years of experience as Chief
Financial Officer at Incyte Corporation, Celgene Corporation,
Scios, Inc., and Cardiac Pathways Corporation and is currently on
the boards of Seattle Genetics, Inc., PDL BioPharma, Inc., and
Aerie Pharmaceuticals, Inc. He brings to the Board valuable and
relevant experience as a senior financial executive at life
sciences and biotechnology companies engaged in financings, global
expansion and other strategic transactions. He also has extensive
knowledge of accounting principles and financial reporting rules
and regulations, tax compliance and oversight of the financial
reporting processes of several large, publicly traded
corporations.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. The Company’s
lead product, EPIDIOLEX® (cannabidiol) oral solution is
commercialized in the U.S. by its U.S. subsidiary Greenwich
Biosciences for the treatment of seizures associated with
Lennox-Gastaut syndrome (LGS), Dravet syndrome or tuberous
sclerosis complex (TSC) in patients one year of age and older. This
product has received approval in the European Union under the
tradename EPIDYOLEX® for the adjunctive treatment of seizures
associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in
conjunction with clobazam in patients two years and older and is
under EMA review for the treatment of TSC. The Company is also
carrying out a Phase 3 trial in Rett syndrome and has a deep
pipeline of additional cannabinoid product candidates, including
nabiximols, for which the Company is advancing multiple late-stage
clinical programs in order to seek FDA approval in the treatment of
spasticity associated with multiple sclerosis and spinal cord
injury, as well as for the treatment of PTSD. The Company has
additional cannabinoid product candidates in Phase 2 trials for
autism and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
|
|
U.S. Media Enquiries:Sam Brown Inc.
Healthcare Communications |
|
Christy CurranMike Beyer |
615 414 8668312 961 2502 |
|
|
UK, EU and ex-U.S. media enquiries |
|
Ben Atwell, FTI Consulting |
+44 (0)203 727 1000 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2024 to May 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From May 2023 to May 2024